First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197

Autores organización

• 

  Betsy Esperanza Castro Cardozo

  Autor

• 

  Juan Carlos Garcia Betancur

  Autor

• 

  Christian Jose Pallares Gutierrez

  Autor

• 

  Maria Virginia Villegas Botero

  Autor

Autores

• Cadena E.D.L.
• Mojica M.F.
• Rojas L.J.
• Marshall S.H.
• Restrepo N.
• Castro-Caro N.P.
• Fonseca-Carrillo M.
• Bonomo R.A.

Unidades de investigación

• Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria RAEH

  

  Investigador

  Maria Virginia Villegas Botero

Resumen

Resistance to ceftazidime-avibactam (CZA) due to Klebsiella pneumoniae carbapenemase (KPC) variants is increasing worldwide. We characterized two CZA-resistant clinical Klebsiella pneumoniae strains by antimicrobial susceptibility test, conjugation assays, and WGS. Isolates belonged to ST258 and ST45, and produced a KPC-31 and a novel variant KPC-197, respectively. The novel KPC variant presents a deletion of two amino acids on the O-loop (del_168–169_EL) and an insertion of two amino acids in position 274 (Ins_274_DS). Continued surveillance of KPC variants conferring CZA resistance in Colombia is warranted. IMPORTANCE Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of Klebsiella pneumoniae carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences. © 2024 De la Cadena et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Keywords

• ceftazidime/avibactam; Klebsiella pneumoniae; KPC variants; whole genome sequencing;Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Colombia; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; amikacin; avibactam; avibactam plus ceftazidime; aztreonam; carbapenemase; ceftazidime; colistin; ertapenem; fosfomycin; gentamicin; imipenem; meropenem; meropenem plus vaborbactam; piperacillin plus tazobactam; relebactam; sulfamethoxazole; tigecycline; trimethoprim; antiinfective agent; avibactam, ceftazidime drug combination; azabicyclo derivative; bacterial protein; beta lactamase; ceftazidime; amino acid sequence; antibiotic resistance; antibiotic sensitivity; Article; bacterium isolate; controlled study; gene sequence; Klebsiella pneumoniae; minimum inhibitory concentration; multilocus sequence typing; nonhuman; phenotype; public health; sequence alignment;